China Medical System Holdings Limited (HKG: 0867)

Market Cap	17.21B
Revenue (ttm)	7.54B
Net Income (ttm)	1.49B
Shares Out	2.42B
EPS (ttm)	0.61
PE Ratio	11.65
Forward PE	8.30
Dividend	0.43 (6.05%)
Ex-Dividend Date	Aug 29, 2024

Volume	4,241,700
Open	6.98
Previous Close	7.12
Day's Range	6.88 - 7.17
52-Week Range	6.23 - 15.86
Beta	0.92
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 12, 2024

About China Medical System Holdings

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of ch...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 5,701
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0867

Financial Performance

In 2023, China Medical System Holdings's revenue was 8.01 billion, a decrease of -12.43% compared to the previous year's 9.15 billion. Earnings were 2.40 billion, a decrease of -26.33%.

Financial numbers in CNY